Restasis Is FDA-Approved, Allergan Reminds Compounder

Law360, New York (January 11, 2018, 8:22 PM EST) -- Allergan USA Inc. on Wednesday urged a California federal court to shoot down false advertising counterclaims brought by drug compounder Imprimis Pharmaceuticals Inc., arguing that it’s factually true that its dry-eye medication Restasis is U.S. Food and Drug Administration-approved.

Allergan said Imprimis’ counterclaims are baseless, as its ads don’t feature the words “FDA-approved,” and even if they did, the statement is true. The counterclaims are in response to Allergan’s suit, which is using the Lanham Act to test the extent to which drug compounders can mass-produce...
To view the full article, register now.




Case Information

Case Title

Allergan USA, Inc. v. Imprimis Pharmaceuticals, Inc.

Case Number



California Central

Nature of Suit

Other Statutory Actions


David O. Carter

Date Filed

September 7, 2017

Law Firms


Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.